International working group on Sarcopenia

Wm C. Chumlea, M. Cesari, W. J. Evans, L. Ferrucci, R. A. Fielding, M. Pahor, S. Studenski, B. Vellas

Research output: Contribution to journalArticle

Abstract

Sarcopenia is the age-related involuntary loss of skeletal muscle mass and functionality that can lead to the development of disability, frailty and increased health care costs. The development of interventions aimed at preventing and/or treating sarcopenia is complex, requiring the adoption of assumptions and standards that are not well established scientifically or clinically. A number of investigators and clinicians (both from academia and industry) met in Rome (Italy) in 2009 to develop a consensus definition of sarcopenia. Subsequently, in Albuquerque (New Mexico, USA) in 2010, the same group met again to consider the complex issues necessary for designing Phase II clinical trials for sarcopenia. Current clinical trial data indicate that fat-free mass (FFM) parameters are responsive to physical activity/nutritional treatment modalities over short time periods, but pharmacological trials of sarcopenia have yet to show significant efficacy. In order to conduct a clinical trial within a reasonable time frame, groups that model or display accelerated aging and loss of FFM are necessary. Few studies have used acceptable designs for testing treatment effects, sample sizes or primary outcomes that could provide interpretable findings or effects across studies. Dual energy x-ray absorptiometry (DXA) is the measure of choice for assessing FFM, but sufficient time is needed for changes to be detected accurately and reliably. A tool set that would allow clinical, basic and epidemiological research on sarcopenia to advance rapidly toward diagnosis and treatment phases should be those reflecting function and strength.

Original languageEnglish (US)
Pages (from-to)450-455
Number of pages6
JournalThe journal of nutrition, health & aging
Volume15
Issue number6
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Sarcopenia
Fats
Clinical Trials
Phase II Clinical Trials
Health Care Costs
Sample Size
Italy
Industry
Skeletal Muscle
Research Personnel
X-Rays
Pharmacology
Research

Keywords

  • fat-free mass
  • frailty
  • phase IIB clinical trials
  • Sarcopenia
  • strength

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Chumlea, W. C., Cesari, M., Evans, W. J., Ferrucci, L., Fielding, R. A., Pahor, M., ... Vellas, B. (2011). International working group on Sarcopenia. The journal of nutrition, health & aging, 15(6), 450-455. https://doi.org/10.1007/s12603-011-0092-7

International working group on Sarcopenia. / Chumlea, Wm C.; Cesari, M.; Evans, W. J.; Ferrucci, L.; Fielding, R. A.; Pahor, M.; Studenski, S.; Vellas, B.

In: The journal of nutrition, health & aging, Vol. 15, No. 6, 06.2011, p. 450-455.

Research output: Contribution to journalArticle

Chumlea, WC, Cesari, M, Evans, WJ, Ferrucci, L, Fielding, RA, Pahor, M, Studenski, S & Vellas, B 2011, 'International working group on Sarcopenia', The journal of nutrition, health & aging, vol. 15, no. 6, pp. 450-455. https://doi.org/10.1007/s12603-011-0092-7
Chumlea WC, Cesari M, Evans WJ, Ferrucci L, Fielding RA, Pahor M et al. International working group on Sarcopenia. The journal of nutrition, health & aging. 2011 Jun;15(6):450-455. https://doi.org/10.1007/s12603-011-0092-7
Chumlea, Wm C. ; Cesari, M. ; Evans, W. J. ; Ferrucci, L. ; Fielding, R. A. ; Pahor, M. ; Studenski, S. ; Vellas, B. / International working group on Sarcopenia. In: The journal of nutrition, health & aging. 2011 ; Vol. 15, No. 6. pp. 450-455.
@article{aceac7995cf44515b0b2df04d7eb3897,
title = "International working group on Sarcopenia",
abstract = "Sarcopenia is the age-related involuntary loss of skeletal muscle mass and functionality that can lead to the development of disability, frailty and increased health care costs. The development of interventions aimed at preventing and/or treating sarcopenia is complex, requiring the adoption of assumptions and standards that are not well established scientifically or clinically. A number of investigators and clinicians (both from academia and industry) met in Rome (Italy) in 2009 to develop a consensus definition of sarcopenia. Subsequently, in Albuquerque (New Mexico, USA) in 2010, the same group met again to consider the complex issues necessary for designing Phase II clinical trials for sarcopenia. Current clinical trial data indicate that fat-free mass (FFM) parameters are responsive to physical activity/nutritional treatment modalities over short time periods, but pharmacological trials of sarcopenia have yet to show significant efficacy. In order to conduct a clinical trial within a reasonable time frame, groups that model or display accelerated aging and loss of FFM are necessary. Few studies have used acceptable designs for testing treatment effects, sample sizes or primary outcomes that could provide interpretable findings or effects across studies. Dual energy x-ray absorptiometry (DXA) is the measure of choice for assessing FFM, but sufficient time is needed for changes to be detected accurately and reliably. A tool set that would allow clinical, basic and epidemiological research on sarcopenia to advance rapidly toward diagnosis and treatment phases should be those reflecting function and strength.",
keywords = "fat-free mass, frailty, phase IIB clinical trials, Sarcopenia, strength",
author = "Chumlea, {Wm C.} and M. Cesari and Evans, {W. J.} and L. Ferrucci and Fielding, {R. A.} and M. Pahor and S. Studenski and B. Vellas",
year = "2011",
month = "6",
doi = "10.1007/s12603-011-0092-7",
language = "English (US)",
volume = "15",
pages = "450--455",
journal = "Journal of Nutrition, Health and Aging",
issn = "1279-7707",
publisher = "Springer Paris",
number = "6",

}

TY - JOUR

T1 - International working group on Sarcopenia

AU - Chumlea, Wm C.

AU - Cesari, M.

AU - Evans, W. J.

AU - Ferrucci, L.

AU - Fielding, R. A.

AU - Pahor, M.

AU - Studenski, S.

AU - Vellas, B.

PY - 2011/6

Y1 - 2011/6

N2 - Sarcopenia is the age-related involuntary loss of skeletal muscle mass and functionality that can lead to the development of disability, frailty and increased health care costs. The development of interventions aimed at preventing and/or treating sarcopenia is complex, requiring the adoption of assumptions and standards that are not well established scientifically or clinically. A number of investigators and clinicians (both from academia and industry) met in Rome (Italy) in 2009 to develop a consensus definition of sarcopenia. Subsequently, in Albuquerque (New Mexico, USA) in 2010, the same group met again to consider the complex issues necessary for designing Phase II clinical trials for sarcopenia. Current clinical trial data indicate that fat-free mass (FFM) parameters are responsive to physical activity/nutritional treatment modalities over short time periods, but pharmacological trials of sarcopenia have yet to show significant efficacy. In order to conduct a clinical trial within a reasonable time frame, groups that model or display accelerated aging and loss of FFM are necessary. Few studies have used acceptable designs for testing treatment effects, sample sizes or primary outcomes that could provide interpretable findings or effects across studies. Dual energy x-ray absorptiometry (DXA) is the measure of choice for assessing FFM, but sufficient time is needed for changes to be detected accurately and reliably. A tool set that would allow clinical, basic and epidemiological research on sarcopenia to advance rapidly toward diagnosis and treatment phases should be those reflecting function and strength.

AB - Sarcopenia is the age-related involuntary loss of skeletal muscle mass and functionality that can lead to the development of disability, frailty and increased health care costs. The development of interventions aimed at preventing and/or treating sarcopenia is complex, requiring the adoption of assumptions and standards that are not well established scientifically or clinically. A number of investigators and clinicians (both from academia and industry) met in Rome (Italy) in 2009 to develop a consensus definition of sarcopenia. Subsequently, in Albuquerque (New Mexico, USA) in 2010, the same group met again to consider the complex issues necessary for designing Phase II clinical trials for sarcopenia. Current clinical trial data indicate that fat-free mass (FFM) parameters are responsive to physical activity/nutritional treatment modalities over short time periods, but pharmacological trials of sarcopenia have yet to show significant efficacy. In order to conduct a clinical trial within a reasonable time frame, groups that model or display accelerated aging and loss of FFM are necessary. Few studies have used acceptable designs for testing treatment effects, sample sizes or primary outcomes that could provide interpretable findings or effects across studies. Dual energy x-ray absorptiometry (DXA) is the measure of choice for assessing FFM, but sufficient time is needed for changes to be detected accurately and reliably. A tool set that would allow clinical, basic and epidemiological research on sarcopenia to advance rapidly toward diagnosis and treatment phases should be those reflecting function and strength.

KW - fat-free mass

KW - frailty

KW - phase IIB clinical trials

KW - Sarcopenia

KW - strength

UR - http://www.scopus.com/inward/record.url?scp=79960138673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960138673&partnerID=8YFLogxK

U2 - 10.1007/s12603-011-0092-7

DO - 10.1007/s12603-011-0092-7

M3 - Article

VL - 15

SP - 450

EP - 455

JO - Journal of Nutrition, Health and Aging

JF - Journal of Nutrition, Health and Aging

SN - 1279-7707

IS - 6

ER -